<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.3.353">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>talks - Sarcopenia in GI Cancers</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
/* CSS for citations */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging-indent div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}</style>


<script src="site_libs/quarto-nav/quarto-nav.js"></script>
<script src="site_libs/quarto-nav/headroom.min.js"></script>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="site_libs/quarto-search/fuse.min.js"></script>
<script src="site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="./">
<script src="site_libs/quarto-html/quarto.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "navbar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "end",
  "type": "overlay",
  "limit": 20,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit"
  }
}</script>


<link rel="stylesheet" href="styles.css">
</head>

<body class="nav-fixed">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
    <nav class="navbar navbar-expand-lg navbar-dark ">
      <div class="navbar-container container-fluid">
      <div class="navbar-brand-container">
    <a class="navbar-brand" href="./index.html">
    <span class="navbar-title">talks</span>
    </a>
  </div>
            <div id="quarto-search" class="" title="Search"></div>
          <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
  <span class="navbar-toggler-icon"></span>
</button>
          <div class="collapse navbar-collapse" id="navbarCollapse">
            <ul class="navbar-nav navbar-nav-scroll me-auto">
  <li class="nav-item">
    <a class="nav-link" href="./index.html" rel="" target="">
 <span class="menu-text">Home</span></a>
  </li>  
  <li class="dropdown-header">
 <span class="menu-text">about.qmd</span></li>
</ul>
            <div class="quarto-navbar-tools ms-auto">
</div>
          </div> <!-- /navcollapse -->
      </div> <!-- /container-fluid -->
    </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article page-navbar">
<!-- sidebar -->
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">On this page</h2>
   
  <ul>
  <li><a href="#sarcopenia-and-mortality-after-gi-cancer-surgery" id="toc-sarcopenia-and-mortality-after-gi-cancer-surgery" class="nav-link active" data-scroll-target="#sarcopenia-and-mortality-after-gi-cancer-surgery">Sarcopenia and mortality after GI Cancer Surgery</a></li>
  <li><a href="#pancreatic-cancer" id="toc-pancreatic-cancer" class="nav-link" data-scroll-target="#pancreatic-cancer">Pancreatic cancer</a>
  <ul class="collapse">
  <li><a href="#peritoperative-morbidity-and-postop-survival" id="toc-peritoperative-morbidity-and-postop-survival" class="nav-link" data-scroll-target="#peritoperative-morbidity-and-postop-survival">Peritoperative morbidity and postop survival</a></li>
  <li><a href="#chemotherapy-toxicity" id="toc-chemotherapy-toxicity" class="nav-link" data-scroll-target="#chemotherapy-toxicity">Chemotherapy Toxicity</a>
  <ul class="collapse">
  <li><a href="#prognostic-value" id="toc-prognostic-value" class="nav-link" data-scroll-target="#prognostic-value">Prognostic value</a></li>
  </ul></li>
  </ul></li>
  <li><a href="#gastric-cancer" id="toc-gastric-cancer" class="nav-link" data-scroll-target="#gastric-cancer">Gastric Cancer</a>
  <ul class="collapse">
  <li><a href="#body-composition-and-therapy-of-advanced-gi-cancers" id="toc-body-composition-and-therapy-of-advanced-gi-cancers" class="nav-link" data-scroll-target="#body-composition-and-therapy-of-advanced-gi-cancers">Body composition and therapy of advanced GI Cancers</a></li>
  <li><a href="#sarcopenia-and-egs-surgery" id="toc-sarcopenia-and-egs-surgery" class="nav-link" data-scroll-target="#sarcopenia-and-egs-surgery">Sarcopenia and EGS Surgery</a></li>
  </ul></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">Sarcopenia in GI Cancers</h1>
</div>



<div class="quarto-title-meta">

    
  
    
  </div>
  

</header>

<section id="sarcopenia-and-mortality-after-gi-cancer-surgery" class="level1">
<h1>Sarcopenia and mortality after GI Cancer Surgery</h1>
<p>Eindhoven cancer registry. Esohpagectomy 90=day mortality 7.1% for &lt;65 years, 8.7% for 65-74 years, and 15.4% for 75+</p>
<p>Mortality should be reported at 90 days Mayo SC, Shore AD, Nathan H, Edil BH, Hirose K, Anders RA, et al.&nbsp;Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford). 2011;13:473–82 Venkat R, Puhan MA, Schulick RD, Cameron JL, Eckhauser FE, Choti MA, et al.&nbsp;Predicting the risk of perioperative mortality in patients undergoing pancreaticoduodenectomy: a novel scoring system. Arch Surg. 2011;146:1277–84 Bryant AS, Rudemiller K, Cerfolio RJ. The 30- versus 90-day operative mortality after pulmonary resection. Ann Thorac Surg. 2010;89: 1717–22; discussion 1722–3</p>
</section>
<section id="pancreatic-cancer" class="level1">
<h1>Pancreatic cancer</h1>
<p>Five-year survival rate 4%</p>
<p>Cachexia is common</p>
<p>Cachexia worsens prognosis in patients with resectable pancreatic cancear (Bachmann JGI Surg 2008)</p>
<section id="peritoperative-morbidity-and-postop-survival" class="level3">
<h3 class="anchored" data-anchor-id="peritoperative-morbidity-and-postop-survival">Peritoperative morbidity and postop survival</h3>
<p>Review of body composition in pancreatic cancer <span class="citation" data-cites="bundred1603">(<a href="#ref-bundred1603" role="doc-biblioref">Bundred, Kamarajah, and Roberts 2019</a>)</span>. Increased risk of morbidity and mortality after surgery and overall survival after surgery. Nine studies of survival in unresectable cancer shows worse survival in non-sarcopenic patients.</p>
</section>
<section id="chemotherapy-toxicity" class="level2">
<h2 class="anchored" data-anchor-id="chemotherapy-toxicity">Chemotherapy Toxicity</h2>
<p>FOLFIRINOX: 82 patients with pancreatic cancer treated with FOLFIRINOX: Shorter survival in sarcopenic patients, especially those with sarcopenia obesity. Worse survival with elevated adipose tissue index (ATI).<span class="citation" data-cites="kurita127">(<a href="#ref-kurita127" role="doc-biblioref">Kurita et al. 2019</a>)</span></p>
<p>Gemcitabine: <span class="citation" data-cites="tan6973">(<a href="#ref-tan6973" role="doc-biblioref">Tan et al. 2009</a>)</span></p>
<p>Impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangio <span class="citation" data-cites="rollins1103">(<a href="#ref-rollins1103" role="doc-biblioref">Rollins et al. 2016</a>)</span> No difference in chemotherapy toxicity in 98 metastatic pancreatic cancer patients</p>
<p>Gemcitabine: 330 patients treated with first-line chemotherapy. SMI and SMD prognostic for survival and chemotherapy toxicity.<span class="citation" data-cites="kim77">(<a href="#ref-kim77" role="doc-biblioref">Kim et al. 2021</a>)</span> SMI cutpoints of Martin 1539. SMD cutpoints 41 and 33 cm2/m2 for non-overweight and overweight patients.<span class="citation" data-cites="martin1539">(<a href="#ref-martin1539" role="doc-biblioref">Martin et al. 2013</a>)</span> Low SMI not associated with survival, but low SMD associated with shorter survival. Patients with low SMI and low SMD have worse survival. ECOG, number of metastatic sites, and chemotherapy drug were prognostic. Grace 3/4 toxicity more common in low SMI (59% vs 43%) and in low SMD (44% vs 60%). SMD was a better prognostic factor. No survival difference according to SMD in responders, but worse survival among non-responders based upon SMD.</p>
<p>Review of 12 articles <span class="citation" data-cites="rizzo974116">(<a href="#ref-rizzo974116" role="doc-biblioref">Rizzo et al. 2022</a>)</span> 4/12 articles showed an association between body composition and chemotherapy-related toxicity</p>
<p>Korea: Palliative chemotherapy among 484 patients <span class="citation" data-cites="choie0139749">(<a href="#ref-choie0139749" role="doc-biblioref">Choi et al. 2015</a>)</span>. Decrease in SMI was present in 61% of men and 41% of women. Decrease in BMI was seen in 37%. Poor prognosis for men was affected by sarcopenia, decline in SMI. Prognosis of women was worsened by overweight at diagnosis, decline in SMI, and decline in BMI. Sarcopenia defined as &lt;42 in men and &lt;33.9 in women using ROC.</p>
<section id="prognostic-value" class="level3">
<h3 class="anchored" data-anchor-id="prognostic-value">Prognostic value</h3>
<p>Sarcopenic obesity adverse prognosticator in pancreatic cancer <span class="citation" data-cites="tan6973">(<a href="#ref-tan6973" role="doc-biblioref">Tan et al. 2009</a>)</span>. 111 patients: 56% sarcopenic, 40% obese, and 16% sarcopenic obesity.</p>
<p>Different outcomes with sarcopenia using Western and Eastern criteria <span class="citation" data-cites="wu862">(<a href="#ref-wu862" role="doc-biblioref">Wu et al. 2019</a>)</span>. Taiwan: 146 patients with newly diagnosed pancreatic cancer. Prevalence of sarcopenia was 66% by Western criteria and 11% by Eastern criteria. Patients sarcopenia by Western criteria had no worse survival than non-sarcopenic, but patients sarcopenic by Eastern criteria had worse survival (p=0.008), and on multivariate analysis accounting for stage (p=0.014)</p>
<p>Ozola Zalite I, Zykus R, Francisco Gonzalez M, Saygili F, Pukitis A, Gaujoux S, Charnley RM, Lyadov V. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology.2015;15(1):19–24.</p>
<p>Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, et al.&nbsp;Prognostic factors for risk stratification of patients with recurrent or metastatic pancreatic adenocarcinoma who were treated with gemcitabinebased chemotherapy. Cancer Res Treat. 2016;48(4):1264–73</p>
</section>
</section>
</section>
<section id="gastric-cancer" class="level1">
<h1>Gastric Cancer</h1>
<p>Non-cancer prognosis after gastrectomy in Japan: Male sex, neutrophil-lymphocyte ratio, skeletal muscel index <span class="citation" data-cites="iida753">(<a href="#ref-iida753" role="doc-biblioref">Iida et al. 2022</a>)</span></p>
<p>PMID 34774016</p>
<section id="body-composition-and-therapy-of-advanced-gi-cancers" class="level3">
<h3 class="anchored" data-anchor-id="body-composition-and-therapy-of-advanced-gi-cancers">Body composition and therapy of advanced GI Cancers</h3>
<p>Low muscle mass has been shown to be associated with poor prognosis cancer patients.<span class="citation" data-cites="martin1539">(<a href="#ref-martin1539" role="doc-biblioref">Martin et al. 2013</a>)</span> This may be due to overal frailty or low muscle mass may lead to increased toxicity from chemotherapy due to pharmacokinetic mechanism. 5-FU is hydrophilic and it volume of distribution includes the muscle compartment, while oxaliplatin is hydrophobic, with distribution in the fat compartment<span class="citation" data-cites="bozzetti2107">(<a href="#ref-bozzetti2107" role="doc-biblioref">Bozzetti 2017</a>)</span>.</p>
<p>In addition, loss of muscle mass during chemotherapy for advanced cancers is a poor prognosticator.</p>
<p>Blauhoff <span class="citation" data-cites="blauwhoff-buskermolen1339">(<a href="#ref-blauwhoff-buskermolen1339" role="doc-biblioref">Blauwhoff-Buskermolen et al. 2016</a>)</span> studis 67 patients with metastatic colorectal cancer. Muscle area on CT decreased by 6.1% over 3 months. Patients in the lowest tertile (loss of 9%) had worse survial. Overall survival 17.5 months for first-line chemotherapy and 8.5months for second-line. Baseline muscle density was predictive of survival on multivariable analysis, but low SMI at baseline was not associatesd with survival. (This may be because sarcopenic obesity is the major risk factor, and there were few obese patients in the study cohort) &gt;Muscle loss of 9% or more remained independently associated with survival when adjusted for sex, age, baseline lactate dehydrogenase concentration, comorbidity, mono-organ or multiorgan metastases, treatment line, and tumor progression at first evaluation by computed tomography scan (hazard ratio, 4.47; 95% CI, 2.21 to 9.05; P , .001). We found a mean coefficient of variation between observers of 0.6% for skeletal muscle area in a random sample of 20 patients, which is regarded to be low.<span class="citation" data-cites="macdonald342">(<a href="#ref-macdonald342" role="doc-biblioref">MacDonald, Greig, and Baracos 2011</a>)</span>. Changes between the first and second scans were calculated as a rate of change per 3 months, meaning change per first evaluation, to compare with available literature.[awad74][prado1583]Relative muscle change per 3 months was categorized into tertiles of muscle change: tertile one, highest muscle loss up to 9%; tertile two, muscle loss of 9% to 1.5%; and tertile three, muscle loss of 1.5% until highest gain in muscle. However, the survival curve of tertile two was not significantly different from the survival curve of tertile three (log-rank P = .961); therefore tertiles two and three were pooled (cutoff, 9% muscle loss).</p>
<p>Awad <span class="citation" data-cites="awad74">(<a href="#ref-awad74" role="doc-biblioref">Awad et al. 2012</a>)</span>studies changes in body composition during neodjuvant chemotherapy for esophagogastric cancer.</p>
<p>Kurk <span class="citation" data-cites="kurk1033">(<a href="#ref-kurk1033" role="doc-biblioref">Kurk et al. 2020</a>)</span> found that skeletal muscle loss during chemotherapy was associated with decreased progression-free and overall- survival in metastatic colorectal cancer.</p>
<blockquote class="blockquote">
<p>Detailed changes in skeletal muscle mass and body weight during CAIRO3 treatments were previously reported.KurkS, p909, 2018) We additionally analyzed changes in SMI and BMI during these treatments by linear mixed effects models.(Bayar MA,p311,2017) The baseline value of the outcome (SMI/BMI) was included in the outcome vector. Potential confounders were age, sex, lactate dehydrogenase (LDH) levels, best response to initial six cycles CAPOX‐B, resection of the primary tumor, and the number of metastatic sites. The final model was selected based on the Akaike Information Criterion (AIC) and included: treatment arm, time, age, sex, resection primary tumor, and the interaction of treatment arm by time as fixed effects. Modeling time as a random effect did not increase the model fit as indicated by the AIC. To investigate differences in SMI and BMI changes over time between the CAIRO3 treatment arms, we checked the significance of the two‐way interaction including treatment arm by time.</p>
</blockquote>
<blockquote class="blockquote">
<p>During p2 (maintenance CAP‐B/observation), again absolute SMI and BMI at the start (t1) of treatment were not associated with early progression and death. In contrast, SMI loss and BMI loss during treatment were associated with early progression and death.</p>
</blockquote>
<p>Fogelman <span class="citation" data-cites="fogelman307">(<a href="#ref-fogelman307" role="doc-biblioref">Fogelman et al. 2014</a>)</span> treated patients undergoing chemotherapy with a novel agent designed to reduce muscle less. CT scans at 2 months were compared with baseline scans prior to chemotherapy.</p>
<blockquote class="blockquote">
<p>Changes in skeletal muscle were determined using routinely acquired CT scans for patients on the study. We calculated skeletal muscle cross-sectional area (cm2) at the third lumbar vertebra (L3). A single slice at the mid-point of L3 was used, preferably a 2.5-mm slice if available, and a 5-mm slice if a 2.5-mm slice was not available. The L3 is a landmark that has been extensively used and validated in studies assessing body composition in cancer patients [<span class="citation" data-cites="shen2333">Shen et al. (<a href="#ref-shen2333" role="doc-biblioref">2004</a>)</span>]<span class="citation" data-cites="prado269">(<a href="#ref-prado269" role="doc-biblioref">C. M. M. Prado, Birdsell, and Baracos 2009</a>)</span> . Skeletal muscle surface areas were determined using Slice-o-Matic softwareTM, version 4.3 (Tomovision, Montreal, QC, Canada) using pre-established thresholds of Hounsfield units (HU) of −29 to +150 <span class="citation" data-cites="mitsiopoulos115">(<a href="#ref-mitsiopoulos115" role="doc-biblioref">Mitsiopoulos et al. 1998</a>)</span>. We additionally evaluated adipose tissue cross-sectional area (subcutaneous, visceral, and intramuscular) in the L3 region as described previously <span class="citation" data-cites="mourtzakis997">(<a href="#ref-mourtzakis997" role="doc-biblioref">Mourtzakis et al. 2008</a>)</span>. Changes in muscle and adipose tissue surface areas over time were determined for each patient from the baseline study to the first CT post treatment, done after 2 months. We looked at muscle loss as a continuous variable and defined “meaningful loss” as greater than a 6 cm2 difference from the baseline to the second scan. We chose this cut point as it is equivalent to 1 kg of skeletal muscle and is associated with physical function (i.e., muscle strength). Additionally, this cut point has been used to investigate significant changes in muscle mass throughout cancer disease trajectory [<span class="citation" data-cites="shen2333">Shen et al. (<a href="#ref-shen2333" role="doc-biblioref">2004</a>)</span>]<span class="citation" data-cites="frontera1038">(<a href="#ref-frontera1038" role="doc-biblioref">Frontera et al. 1988</a>)</span><span class="citation" data-cites="prado1012">(<a href="#ref-prado1012" role="doc-biblioref">C. M. Prado et al. 2013</a>)</span>.</p>
</blockquote>
<p>Prado <span class="citation" data-cites="prado1012">(<a href="#ref-prado1012" role="doc-biblioref">C. M. Prado et al. 2013</a>)</span> looked at changes in 1279 CT scans in 368 patients with advanced cancer. The last available interval with CT scans was chosen for comparison. Categorized into stable, gaining, losing for muscle and for adipose tissue. Adipose tissue was ?? sum of visceral adipose tissue and subcutaneous tissue. (<strong>Did not use SMI</strong>). Muscel loss and adipose loss seemed correlated, with larger magnitude of adipose tissue loss at short interval to death. (Authors conclusion that muscle and adipose tissue loss in the past 3 months of life is likely not possible) &gt;Advanced-cancer patients (n = 368; median survival: 196 d) had a total of 1279 CT images over the course of their disease. With consideration of all time points, muscle loss occurred in 39% of intervals between any 2 scans. However, the overall frequency of muscle gain was 15.4%, and muscle was stable in 45.6% of intervals between any 2 scans, which made the maintenance or gain of muscle the predominant behavior. Multinomial logistic regression revealed that being within 90 d (compared with &gt;90 d) from death was the principal risk factor for muscle loss (OR: 2.67; 95% CI: 1.45, 4.94; P = 0.002), and muscle gain was correspondingly less likely (OR: 0.37; 95% CI: 0.20, 0.69; P = 0.002) at this time. Sex, age, BMI, and tumor group were not significant predictors of muscle loss or gain. A much higher proportion of men (61%) than women (31%) met the criteria for sarcopenia. Changes in muscle and adipose tissue over time were calculated as the absolute loss or gain of tissue area during each scan interval. The precision error of measurements was ~1.5% <span class="citation" data-cites="mourtzakis997">(<a href="#ref-mourtzakis997" role="doc-biblioref">Mourtzakis et al. 2008</a>)</span> with a minimum detectable change of ~3 cm2. We attributed the change during each interval into the following categories: 1) muscle loss ≥6.0 cm2, 2) stable muscle ±5.9 cm2, or 3) muscle gain ≥6.0cm2. These cutoffs are equivalent to a loss or gain of ≥1 kg of skeletal muscle on a whole-body basis and are associated with alterations in muscle strength [<span class="citation" data-cites="shen2333">Shen et al. (<a href="#ref-shen2333" role="doc-biblioref">2004</a>)</span>]<span class="citation" data-cites="frontera1038">(<a href="#ref-frontera1038" role="doc-biblioref">Frontera et al. 1988</a>)</span>. For adipose tissue, categories were based on the equivalence of 14.7 cm2 total fat at L3 and 1 kg tissue on a whole-body basis <span class="citation" data-cites="shen2333">(<a href="#ref-shen2333" role="doc-biblioref">Shen et al. 2004</a>)</span>; therefore, changes during each interval were categorized as 1) adipose tissue loss ≥14.7 cm2, 2) stable adipose tissue ±14.6 cm2, or 3) adipose tissue gain ≥14.7 cm2. CT scans were taken for the diagnosis, confirmation of stage, and follow-up of disease progression and treatment. With the understanding that cachexia evolves markedly in the end of life and to take advantage of repeated measures, we focused on patients with ≥2 CT images (2–6 images) on record during the year preceding their deaths (n = 368). A selection bias was not apparent in this sample; we showed that the sex distribution, age at death, survival time, primary tumor site, tumor morphology, and body-composition features (ie, muscle and adipose tissues) in patients who had only a single scan were not different from those of the overall cohort at an equal time to death (P &gt; 0.1). Patients included in the analysis (n = 368) were of advanced stage, and the median time to death of all groups was &lt;1 y.</p>
<p>Similar study by Tan looking at longitudinal body composition in pancreatic cancer <span class="citation" data-cites="tan6973">(<a href="#ref-tan6973" role="doc-biblioref">Tan et al. 2009</a>)</span>. 111 patients with metastatic pancreatic cancer: 44 identified with more than one scan. Patients who underwent repeated CT scans were more likely to receive active therapy (71%) and had longer survival than those who had a solitary CT scan (28% receiving active chemotherapy). OVeral median survival 130 days. Age and sarcopenic obesity predicted survival. Sarcopenic obesity had survival of 55 days vs 148 days for those without sarcopenia obesity. Muscle loss was normalized to percent during 100 days. Median interval between scans was ??135 days. Patients grouped in tertiles for muscle gain/loss. Top tertile gained 7% muscle cross-sectional area/100 days, while bottom tertile lost 12% over 100 days. All tertiles lost adipose tissue. <strong>No difference in survival between the tertiles.</strong> &gt; muscle loss was the prevalent behavior, but 14% of patients with metastatic pancreatic cancer (considered the disease most highly associated with cachexia) exhibited a muscle gain of 7.9 ± 14.4%/100 d).</p>
<p>Lieffers and advanced colorectal cancer: Found liver and spleen increased in size in terminal patients (causing increase in basal metabolic rate). Found more rapid muscle loss with progressive disease <span class="citation" data-cites="lieffers1173">(<a href="#ref-lieffers1173" role="doc-biblioref">Lieffers et al. 2009</a>)</span>. Different thresholds for VAT (-150 to -50) and SAT(-190 to -30). Also estimated muscel surface area using measurements 5cm above L4<span class="citation" data-cites="shen2333">(<a href="#ref-shen2333" role="doc-biblioref">Shen et al. 2004</a>)</span>. Most rapid change in body composition between 4 months and 1 month prior to death. &gt;14% of patients gained skeletal muscle during the year preceding death from colorectal cancer (+4.7 ± 5.4%/100 d).</p>
<p>Longitudinal study of patients with advanced non-small cell lung cancer (all with &lt;1yr survival). <span class="citation" data-cites="baracos1133S">(<a href="#ref-baracos1133S" role="doc-biblioref">Baracos et al. 2010</a>)</span> &gt;At referral (median time to death: 265 d), mean body mass index (BMI; in kg/m(2)) was 24.9, with 47.4% of patients being overweight or obese. Only 7.5% overall were underweight as conventionally understood (BMI &lt; 18.5). Analysis of computed tomography images showed extremely high heterogeneity of muscle mass within all strata of BMI. The overall prevalence of severe muscle depletion (sarcopenia) was 46.8% and was present in patients in all BMI categories.</p>
<p>Caan <span class="citation" data-cites="caan1008">(<a href="#ref-caan1008" role="doc-biblioref">Caan et al. 2017</a>)</span> examined body composition and survival from colorecal cncer at Kaiser.</p>
</section>
<section id="sarcopenia-and-egs-surgery" class="level2">
<h2 class="anchored" data-anchor-id="sarcopenia-and-egs-surgery">Sarcopenia and EGS Surgery</h2>
<p>Necrotizing soft-tissue infections <span class="citation" data-cites="castilloangeles31">(<a href="#ref-castilloangeles31" role="doc-biblioref"><strong>castilloangeles31?</strong></a>)</span></p>
<p>Ambominal and emergency surgery <span class="citation" data-cites="hajibandeh370">(<a href="#ref-hajibandeh370" role="doc-biblioref">Hajibandeh et al. 2019</a>)</span></p>



</section>
</section>

<div id="quarto-appendix" class="default"><section class="quarto-appendix-contents" role="doc-bibliography"><h2 class="anchored quarto-appendix-heading">References</h2><div id="refs" class="references csl-bib-body hanging-indent" role="list">
<div id="ref-awad74" class="csl-entry" role="listitem">
Awad, Sherif, Benjamin H. Tan, Helen Cui, Ashish Bhalla, Kenneth C. H. Fearon, Simon L. Parsons, James A. Catton, and Dileep N. Lobo. 2012. <span>“Marked Changes in Body Composition Following Neoadjuvant Chemotherapy for Oesophagogastric Cancer.”</span> <em>Clinical Nutrition (Edinburgh, Scotland)</em> 31 (1): 74–77. <a href="https://doi.org/10.1016/j.clnu.2011.08.008">https://doi.org/10.1016/j.clnu.2011.08.008</a>.
</div>
<div id="ref-baracos1133S" class="csl-entry" role="listitem">
Baracos, Vickie E., Tony Reiman, Marina Mourtzakis, Ioannis Gioulbasanis, and Sami Antoun. 2010. <span>“Body Composition in Patients with Non-Small Cell Lung Cancer: A Contemporary View of Cancer Cachexia with the Use of Computed Tomography Image Analysis.”</span> <em>The American Journal of Clinical Nutrition</em> 91 (4): 1133S–1137S. <a href="https://doi.org/10.3945/ajcn.2010.28608C">https://doi.org/10.3945/ajcn.2010.28608C</a>.
</div>
<div id="ref-blauwhoff-buskermolen1339" class="csl-entry" role="listitem">
Blauwhoff-Buskermolen, Susanne, Kathelijn S. Versteeg, Marian A. E. de van der Schueren, Nicole R. den Braver, Johannes Berkhof, Jacqueline A. E. Langius, and Henk M. W. Verheul. 2016. <span>“Loss of <span>Muscle Mass During Chemotherapy Is Predictive</span> for <span>Poor Survival</span> of <span>Patients With Metastatic Colorectal Cancer</span>.”</span> <em>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</em> 34 (12): 1339–44. <a href="https://doi.org/10.1200/JCO.2015.63.6043">https://doi.org/10.1200/JCO.2015.63.6043</a>.
</div>
<div id="ref-bozzetti2107" class="csl-entry" role="listitem">
Bozzetti, F. 2017. <span>“Forcing the Vicious Circle: Sarcopenia Increases Toxicity, Decreases Response to Chemotherapy and Worsens with Chemotherapy.”</span> <em>Annals of Oncology: Official Journal of the European Society for Medical Oncology</em> 28 (9): 2107–18. <a href="https://doi.org/10.1093/annonc/mdx271">https://doi.org/10.1093/annonc/mdx271</a>.
</div>
<div id="ref-bundred1603" class="csl-entry" role="listitem">
Bundred, James, Sivesh K. Kamarajah, and Keith J. Roberts. 2019. <span>“Body Composition Assessment and Sarcopenia in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis.”</span> <em>HPB</em> 21 (12): 1603–12. <a href="https://doi.org/10.1016/j.hpb.2019.05.018">https://doi.org/10.1016/j.hpb.2019.05.018</a>.
</div>
<div id="ref-caan1008" class="csl-entry" role="listitem">
Caan, Bette J., Jeffrey A. Meyerhardt, Candyce H. Kroenke, Stacey Alexeeff, Jingjie Xiao, Erin Weltzien, Elizabeth Cespedes Feliciano, et al. 2017. <span>“Explaining the <span>Obesity Paradox</span>: <span>The Association</span> Between <span>Body Composition</span> and <span>Colorectal Cancer Survival</span> (<span>C-SCANS Study</span>).”</span> <em>Cancer Epidemiology, Biomarkers &amp; Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology</em> 26 (7): 1008–15. <a href="https://doi.org/10.1158/1055-9965.EPI-17-0200">https://doi.org/10.1158/1055-9965.EPI-17-0200</a>.
</div>
<div id="ref-choie0139749" class="csl-entry" role="listitem">
Choi, Younak, Do-Youn Oh, Tae-Yong Kim, Kyung-Hun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, and Yung-Jue Bang. 2015. <span>“Skeletal <span>Muscle Depletion Predicts</span> the <span>Prognosis</span> of <span>Patients</span> with <span>Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy</span>, <span>Independent</span> of <span>Body Mass Index</span>.”</span> <em>PloS One</em> 10 (10): e0139749. <a href="https://doi.org/10.1371/journal.pone.0139749">https://doi.org/10.1371/journal.pone.0139749</a>.
</div>
<div id="ref-fogelman307" class="csl-entry" role="listitem">
Fogelman, David R., Holly Holmes, Khalil Mohammed, Matthew H. G. Katz, Carla M. Prado, Jessica Lieffers, Naveen Garg, et al. 2014. <span>“Does <span>IGFR1</span> Inhibition Result in Increased Muscle Mass Loss in Patients Undergoing Treatment for Pancreatic Cancer?”</span> <em>Journal of Cachexia, Sarcopenia and Muscle</em> 5 (4): 307–13. <a href="https://doi.org/10.1007/s13539-014-0145-y">https://doi.org/10.1007/s13539-014-0145-y</a>.
</div>
<div id="ref-frontera1038" class="csl-entry" role="listitem">
Frontera, W. R., C. N. Meredith, K. P. O’Reilly, H. G. Knuttgen, and W. J. Evans. 1988. <span>“Strength Conditioning in Older Men: Skeletal Muscle Hypertrophy and Improved Function.”</span> <em>Journal of Applied Physiology (Bethesda, Md.: 1985)</em> 64 (3): 1038–44. <a href="https://doi.org/10.1152/jappl.1988.64.3.1038">https://doi.org/10.1152/jappl.1988.64.3.1038</a>.
</div>
<div id="ref-hajibandeh370" class="csl-entry" role="listitem">
Hajibandeh, Shahab, Shahin Hajibandeh, Ross Jarvis, Talvinder Bhogal, and Sanjush Dalmia. 2019. <span>“Meta-Analysis of the Effect of Sarcopenia in Predicting Postoperative Mortality in Emergency and Elective Abdominal Surgery.”</span> <em>The Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland</em> 17 (6): 370–80. <a href="https://doi.org/10.1016/j.surge.2018.09.003">https://doi.org/10.1016/j.surge.2018.09.003</a>.
</div>
<div id="ref-iida753" class="csl-entry" role="listitem">
Iida, Michihisa, Shigeru Takeda, Chiyo Nakashima, Mitsuo Nishiyama, Yusaku Watanabe, Nobuaki Suzuki, Shigefumi Yoshino, Yuki Nakagami, Tsuyoshi Tanabe, and Hiroaki Nagano. 2022. <span>“Risk Factors for Non-Gastric-Cancer-Related Death After Gastrectomy in Elderly Patients.”</span> <em>Annals of Gastroenterological Surgery</em> 6 (6): 753–66. <a href="https://doi.org/10.1002/ags3.12588">https://doi.org/10.1002/ags3.12588</a>.
</div>
<div id="ref-kim77" class="csl-entry" role="listitem">
Kim, In-Ho, Moon Hyung Choi, In Seok Lee, Tae Ho Hong, and Myung Ah. Lee. 2021. <span>“Clinical Significance of Skeletal Muscle Density and Sarcopenia in Patients with Pancreatic Cancer Undergoing First-Line Chemotherapy: A Retrospective Observational Study.”</span> <em>BMC Cancer</em> 21 (January): 77. <a href="https://doi.org/10.1186/s12885-020-07753-w">https://doi.org/10.1186/s12885-020-07753-w</a>.
</div>
<div id="ref-kurita127" class="csl-entry" role="listitem">
Kurita, Yusuke, Noritoshi Kobayashi, Motohiko Tokuhisa, Ayumu Goto, Kensuke Kubota, Itaru Endo, Atsushi Nakajima, and Yasushi Ichikawa. 2019. <span>“Sarcopenia Is a Reliable Prognostic Factor in Patients with Advanced Pancreatic Cancer Receiving <span>FOLFIRINOX</span> Chemotherapy.”</span> <em>Pancreatology</em> 19 (1): 127–35. <a href="https://doi.org/10.1016/j.pan.2018.11.001">https://doi.org/10.1016/j.pan.2018.11.001</a>.
</div>
<div id="ref-kurk1033" class="csl-entry" role="listitem">
Kurk, Sophie A., Petra H. M. Peeters, Bram Dorresteijn, Pim A. de Jong, Marion Jourdan, Geert-Jan M. Creemers, Frans L. G. Erdkamp, et al. 2020. <span>“Loss of Skeletal Muscle Index and Survival in Patients with Metastatic Colorectal Cancer: <span>Secondary</span> Analysis of the Phase 3 <span>CAIRO3</span> Trial.”</span> <em>Cancer Medicine</em> 9 (3): 1033–43. <a href="https://doi.org/10.1002/cam4.2787">https://doi.org/10.1002/cam4.2787</a>.
</div>
<div id="ref-lieffers1173" class="csl-entry" role="listitem">
Lieffers, Jessica R., Marina Mourtzakis, Kevin D. Hall, Linda J. McCargar, Carla M. M. Prado, and Vickie E. Baracos. 2009. <span>“A Viscerally Driven Cachexia Syndrome in Patients with Advanced Colorectal Cancer: Contributions of Organ and Tumor Mass to Whole-Body Energy Demands.”</span> <em>The American Journal of Clinical Nutrition</em> 89 (4): 1173–79. <a href="https://doi.org/10.3945/ajcn.2008.27273">https://doi.org/10.3945/ajcn.2008.27273</a>.
</div>
<div id="ref-macdonald342" class="csl-entry" role="listitem">
MacDonald, Alisdair J., Carolyn A. Greig, and Vickie Baracos. 2011. <span>“The Advantages and Limitations of Cross-Sectional Body Composition Analysis.”</span> <em>Current Opinion in Supportive and Palliative Care</em> 5 (4): 342–49. <a href="https://doi.org/10.1097/SPC.0b013e32834c49eb">https://doi.org/10.1097/SPC.0b013e32834c49eb</a>.
</div>
<div id="ref-martin1539" class="csl-entry" role="listitem">
Martin, Lisa, Laura Birdsell, Neil Macdonald, Tony Reiman, M. Thomas Clandinin, Linda J. McCargar, Rachel Murphy, Sunita Ghosh, Michael B. Sawyer, and Vickie E. Baracos. 2013. <span>“Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index.”</span> <em>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology</em> 31 (12): 1539–47. <a href="https://doi.org/10.1200/JCO.2012.45.2722">https://doi.org/10.1200/JCO.2012.45.2722</a>.
</div>
<div id="ref-mitsiopoulos115" class="csl-entry" role="listitem">
Mitsiopoulos, N., R. N. Baumgartner, S. B. Heymsfield, W. Lyons, D. Gallagher, and R. Ross. 1998. <span>“Cadaver Validation of Skeletal Muscle Measurement by Magnetic Resonance Imaging and Computerized Tomography.”</span> <em>Journal of Applied Physiology (Bethesda, Md.: 1985)</em> 85 (1): 115–22. <a href="https://doi.org/10.1152/jappl.1998.85.1.115">https://doi.org/10.1152/jappl.1998.85.1.115</a>.
</div>
<div id="ref-mourtzakis997" class="csl-entry" role="listitem">
Mourtzakis, Marina, Carla M. M. Prado, Jessica R. Lieffers, Tony Reiman, Linda J. McCargar, and Vickie E. Baracos. 2008. <span>“A Practical and Precise Approach to Quantification of Body Composition in Cancer Patients Using Computed Tomography Images Acquired During Routine Care.”</span> <em>Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition Et Metabolisme</em> 33 (5): 997–1006. <a href="https://doi.org/10.1139/H08-075">https://doi.org/10.1139/H08-075</a>.
</div>
<div id="ref-prado269" class="csl-entry" role="listitem">
Prado, Carla M. M., Laura A. Birdsell, and Vickie E. Baracos. 2009. <span>“The Emerging Role of Computerized Tomography in Assessing Cancer Cachexia.”</span> <em>Current Opinion in Supportive and Palliative Care</em> 3 (4): 269–75. <a href="https://doi.org/10.1097/SPC.0b013e328331124a">https://doi.org/10.1097/SPC.0b013e328331124a</a>.
</div>
<div id="ref-prado1012" class="csl-entry" role="listitem">
Prado, Carla M., Michael B. Sawyer, Sunita Ghosh, Jessica R. Lieffers, Nina Esfandiari, Sami Antoun, and Vickie E. Baracos. 2013. <span>“Central Tenet of Cancer Cachexia Therapy: Do Patients with Advanced Cancer Have Exploitable Anabolic Potential?”</span> <em>The American Journal of Clinical Nutrition</em> 98 (4): 1012–19. <a href="https://doi.org/10.3945/ajcn.113.060228">https://doi.org/10.3945/ajcn.113.060228</a>.
</div>
<div id="ref-rizzo974116" class="csl-entry" role="listitem">
Rizzo, Stefania, Isabel Scala, Angela Rodriguez Robayo, Marco Cefalì, Sara De Dosso, Stefano Cappio, Genti Xhepa, and Filippo Del Grande. 2022. <span>“Body Composition as a Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients: <span>A</span> Systematic Review.”</span> <em>Frontiers in Oncology</em> 12 (September): 974116. <a href="https://doi.org/10.3389/fonc.2022.974116">https://doi.org/10.3389/fonc.2022.974116</a>.
</div>
<div id="ref-rollins1103" class="csl-entry" role="listitem">
Rollins, Katie E., Nilanjana Tewari, Abigail Ackner, Amir Awwad, Srinivasan Madhusudan, Ian A. Macdonald, Kenneth C. H. Fearon, and Dileep N. Lobo. 2016. <span>“The Impact of Sarcopenia and Myosteatosis on Outcomes of Unresectable Pancreatic Cancer or Distal Cholangiocarcinoma.”</span> <em>Clinical Nutrition</em> 35 (5): 1103–9. <a href="https://doi.org/10.1016/j.clnu.2015.08.005">https://doi.org/10.1016/j.clnu.2015.08.005</a>.
</div>
<div id="ref-shen2333" class="csl-entry" role="listitem">
Shen, Wei, Mark Punyanitya, ZiMian Wang, Dympna Gallagher, Marie-Pierre St-Onge, Jeanine Albu, Steven B. Heymsfield, and Stanley Heshka. 2004. <span>“Total Body Skeletal Muscle and Adipose Tissue Volumes: Estimation from a Single Abdominal Cross-Sectional Image.”</span> <em>Journal of Applied Physiology (Bethesda, Md.: 1985)</em> 97 (6): 2333–38. <a href="https://doi.org/10.1152/japplphysiol.00744.2004">https://doi.org/10.1152/japplphysiol.00744.2004</a>.
</div>
<div id="ref-tan6973" class="csl-entry" role="listitem">
Tan, Benjamin H. L., Laura A. Birdsell, Lisa Martin, Vickie E. Baracos, and Kenneth C. H. Fearon. 2009. <span>“Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer.”</span> <em>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</em> 15 (22): 6973–79. <a href="https://doi.org/10.1158/1078-0432.CCR-09-1525">https://doi.org/10.1158/1078-0432.CCR-09-1525</a>.
</div>
<div id="ref-wu862" class="csl-entry" role="listitem">
Wu, Chih-Horng, Ming-Chu Chang, Vladimir K. Lyadov, Po-Chin Liang, Chyi-Mong Chen, Tiffany Ting-Fang Shih, and Yu-Ting Chang. 2019. <span>“Comparing <span>Western</span> and <span>Eastern</span> Criteria for Sarcopenia and Their Association with Survival in Patients with Pancreatic Cancer.”</span> <em>Clinical Nutrition (Edinburgh, Scotland)</em> 38 (2): 862–69. <a href="https://doi.org/10.1016/j.clnu.2018.02.016">https://doi.org/10.1016/j.clnu.2018.02.016</a>.
</div>
</div></section></div></main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    text: function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>